key: cord-0892384-spkadf7b
authors: Jara, Luis M.; Ferradas, Cusi; Schiaffino, Francesca; Sánchez-Carrión, Camila; Martinez-Vela, Ana; Ulloa, Alexandra; Isasi-Rivas, Gisela; Montalván, Angela; Sarmiento, Luis Guevara; Fernández, Manolo; Zimic, Mirko
title: Evidence of neutralizing antibodies against SARS-CoV-2 in domestic cats living with owners with a history of COVID-19 in Lima – Peru
date: 2021-08-26
journal: One Health
DOI: 10.1016/j.onehlt.2021.100318
sha: 1246b7669b481f909de2254b35b0fc463ae7003d
doc_id: 892384
cord_uid: spkadf7b

SARS-CoV-2 can infect a variety of wild and domestic animals worldwide. Of these, domestic cats are highly susceptible species and potential viral reservoirs. As such, it is important to investigate disease exposure in domestic cats in areas with active community transmission and high disease prevalence. In this report we demonstrate the presence of serum neutralizing antibodies against the receptor binding-domain (RBD) of the SARS-CoV-2 in cats whose owners had been infected with SARS-CoV-2 in Lima, Peru, using a commercial competitive ELISA SARS-CoV-2 Surrogate Virus Neutralization Test. Out of 41 samples, 17.1% (7/41) and 31.7% (13/41) were positive, using the cut-off inhibition value of 30% and 20%, respectively. Not all cats living in a single house had detectable neutralizing antibodies showing heterogenous exposure and immunity among cohabiting animals. This is the first report of SARS-COV-2 exposure of domestic cats in Lima, Peru. Further studies are required to ascertain the prevalence of SARS-COV-2 exposure among domestic cats.

considered the most susceptible species because of the higher similarity of the angiotensinconverting enzyme 2 (ACE2) between these species and humans [7] . Although the majority of infected cats are asymptomatic, some animals may develop clinical disease, and the virus can be experimentally transmitted between individuals [8] . Therefore, SARS-CoV-2 could have a direct impact on animal health, while the possibility of cats becoming zoonotic reservoirs has not been totally discarded.

Serological testing is a valuable tool for screening antibody levels associated with pathogen exposure. As with other viral infections, host neutralizing serum antibodies may block the binding of viral proteins to cell surface receptors. In humans, SARS-CoV-2 neutralizing antibodies have been determined to inversely correlate with disease severity and can predict the probability of re-infections [9] . In animals, reported prevalence of neutralizing serum antibodies against SARS-CoV-2 in cats varies, with as low as 0.002% in Germany, 0.2% in Brazil, 5.8% in Italy, and 10.8% in Wuhan, . In Peru, one of the most affected countries by the COVID-19 pandemic, no previous studies have been conducted investigating the seroprevalence or prevalence of SARS-CoV-2 among domestic cats. In this report we demonstrate the presence of serum neutralizing antibodies against the receptor binding-domain (RBD) of the SARS-CoV-2 viral spike protein in cats whose owners confirmed previous infection with SARS-CoV-2.

J o u r n a l P r e -p r o o f Journal Pre-proof

Blood samples of cats seeking routine veterinary care were collected between August 2020 and April 2021 from three veterinary clinics in Lima, Peru. All cat owners signed an informed consent authorizing the use of the samples for research purposes. Samples were centrifuged at 3500 rpm for 5 minutes and the serum supernatant was transferred to microcentrifuge tubes and was stored at -20 o C. Samples from cats whose owners confirmed previous COVID-19 disease (clinical signs with positive IgG/IgM rapid test or qRT-PCR) during veterinary anamnesis were conveniently selected. To test the serum samples for the presence of neutralizing antibodies against the RBD of the viral spike protein, a commercial competitive ELISA cPass™ SARS-CoV-2 Neutralization Antibody Detection Kit also known as SARS-CoV-2 Surrogate Virus Neutralization Test (sVNT) Kit was used according to the manufacturer's instructions (Genscript, New Jersey, USA). Percent serum neutralization was calculated as follows: = (1 -OD value of sample / OD value of negative control) × 100%. A cut-off value of 20% and an updated 30% of inhibition were used to establish positivity. This study was approved by the Universidad Peruana Cayetano Heredia Animal Care and Use Ethical Committee (N° 027-08-20). Out of 13 positive samples, 38.4% (5/13) showed clinical signs including sneezing and dyspnea, cough, vomit, or depression. Interestingly, one of the animals with the highest percent neutralization (73.06%) showed all the symptoms described. A subclinical infection, with a prolonged period of oral and nasal viral shedding that is generally not accompanied by symptomatology has been reported in cats [14] . Only 8 out 22 cats in household C had evidence of serum neutralizing antibodies. This suggests that infection may not be homogenous among cohabiting animals, and this could be associated with other factors such as health state, immunity, proximity to the infected owner(s), among others.

Our results show compelling evidence of SARS-CoV-2 exposure in domestic cats and it is the first report of such an event in Peru. Percent seropositivity in this population of cats is high compared to other studies published, such as that of Italy and Wuhan, China, in which 5.8% of 191 cats 10.8% of 102 cats had neutralizing antibodies, respectively [12, 13] .

However, these studies were not exclusively done on a pet population living with COVID-19 infected owners. In a longitudinal cohort study of pets living with COVID-19 owners conducted in Texas, USA, 43.8% of 16 cats developed neutralizing antibodies against SARS-CoV-2 [15] , percentage that is closer to the results obtained in this study. Serum neutralization activity is commonly tested using plaque reduction neutralization tests (PRNT) as gold standard. However, the commercial assay utilized in this preliminary study has shown a high correlation with serum neutralization activity using PRNT J o u r n a l P r e -p r o o f Journal Pre-proof and has shown robust internal validity parameters for both humans, cats, dogs and hamster sera [17, 18] . Additionally, this test has already been used in a large-scale serological survey in cats in Thailand using 20% of inhibition as the cut-off value [19] . Our study reports results based on both a 20% and a 30% inhibition cut-off value, based on the manufacturer's recommendation. Moreover, moderate to high sensitivity and specificity of the sVNT has been reported using this cut-off value correction (30%) in samples from multiple animal species (ferrets, cats, minks, hamster). Specifically, the specificity was 99% and 100% using 20% and 30% cut-off values, respectively [20] . The sensitivity of the sVNT using a cut-off value of 20% was 98.9% and 97% when compared to PRNT 90 and PRNT 50 , respectively, yet sensitivity decreased to 93.9% when using a 30% of cut-off value (compared to PRNT 50 ) [17] . Additionally, this commercial assay offers logistical and biosafety advantages for researchers working in resource-limited settings that do not have access to a BSL-3 containment required for SARS-CoV-2 manipulation.

The animals evaluated in our study sought routine veterinary care that was not associated with symptomatic respiratory disease in most of the cases, demonstrating potential asymptomatic infection in cats, and consequently, potential viral reservoirs. In some studies, over 21% and 25% of infected households sampled had pets with neutralizing antibodies [15, 21] . Few case studies of natural infection in cats document severe clinical outcomes, and those that have revealed that co-morbidities likely played a contributing factor in illness or death [15] . Seroprevalence studies should be conducted in affected regions to monitor SARS-CoV-2 asymptomatic infections in pets such as cats, ferrets, or dogs, especially in companion animals living with . 

SARS-CoV-2 infection of Chinese hamsters (Cricetulus griseus) reproduces COVID-19 pneumonia in a well-established small animal model

An Overview of SARS-CoV-2 and Animal Infection

Transmission of SARS-CoV-2 on mink farms between humans and mink and back to humans

Complete Genome Sequence of SARS-CoV-2 in a Tiger from a U.S. Zoological Collection, Microbiol Resour Announc

Susceptibility of livestock and companion animals to COVID-19

Transmission of SARS-CoV-2 in Domestic Cats

Disease severity dictates SARS-CoV-2-specific neutralizing antibody responses in COVID-19

Neutralizing antibodies for SARS-CoV-2 in stray animals from Rio de Janeiro, Brazil

Evidence of exposure to SARS-CoV-2 in cats and dogs from households in Italy

A serological survey of SARS-CoV-2 in cat in Wuhan

SARS-CoV-2 in animals: potential for unknown reservoir hosts and public health implications

SARS-CoV-2 Infections and Viral Isolations among Serially Tested Cats and Dogs in Households with

Experimental infection of domestic dogs and cats with SARS-CoV-2: Pathogenesis, transmission, and response to reexposure in cats

A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction

Serological survey of antibodies against SARS-CoV-2 in dogs and cats

Evaluation of a multi-species SARS-CoV-2 surrogate virus neutralization test, One Health

SARS-CoV-2 host diversity: An update of natural infections and experimental evidence